 - Cancer-directed therapy chemo-, radio-, immuno-, biologic, or hormonal therapy with the exception of luteinizing hormone-releasing hormone agonistsantagonists, receptor activator of nuclear factor kappa-B ligand inhibitors, and bisphosphonates within 21 days or 5 half-lives, whichever is longer, before the first BOS172722 or paclitaxel dose Palliative radiotherapy is allowed before initiating study treatment if any associated toxicity resolved to Grade 1. 